<DOC>
	<DOCNO>NCT00958412</DOCNO>
	<brief_summary>This extension phase II , three-arm , parallel design , dose-ranging , placebo-controlled , randomize , double-blind , multicenter study placebo one ( 1 ) two ( 2 ) dose level Proellex® administer once-daily four ( 4 ) month .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Proellex® Treatment Endometriosis-extension Study</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<criteria>Only subject treat ZPE201 study allow enter extension study . Subjects withdraw ZPE201 due lack treatment efficacy also invite participate . All subject</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Oral progesterone blocker</keyword>
</DOC>